Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Vitamin D Modifies the Incidence of Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation Depending on the Vitamin D Receptor (VDR) Polymorphisms.

Carrillo-Cruz E, García-Lozano JR, Márquez-Malaver FJ, Sánchez-Guijo FM, Montero Cuadrado I, Ferra I Coll C, Valcárcel D, López-Godino O, Cuesta M, Parody R, López-Corral L, Alcoceba M, Caballero-Velázquez T, Rodríguez-Gil A, Bejarano-García JA, Ramos TL, Pérez-Simón JA.

Clin Cancer Res. 2019 Aug 1;25(15):4616-4623. doi: 10.1158/1078-0432.CCR-18-3875. Epub 2019 May 1.

PMID:
31043390
2.

Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease.

Garcia-Gomez A, De Las Rivas J, Ocio EM, Díaz-Rodríguez E, Montero JC, Martín M, Blanco JF, Sanchez-Guijo FM, Pandiella A, San Miguel JF, Garayoa M.

Oncotarget. 2014 Sep 30;5(18):8284-305.

3.

Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome.

Bernal T, Diez-Campelo M, Godoy V, Rojas S, Colado E, Alcoceba M, González M, Vidriales B, Sánchez-Guijo FM, López-Corral L, Luño E, del Cañizo C.

Leuk Res. 2014 May;38(5):551-6. doi: 10.1016/j.leukres.2014.02.001. Epub 2014 Feb 10.

PMID:
24655806
4.

Unrelated cord blood transplantation: outcomes after single-unit intrabone injection compared with double-unit intravenous injection in patients with hematological malignancies.

Rocha V, Labopin M, Ruggeri A, Podestà M, Gallamini A, Bonifazi F, Sanchez-Guijo FM, Rovira M, Socie G, Baltadakis I, Michallet M, Deconinck E, Bacigalupo A, Mohty M, Gluckman E, Frassoni F.

Transplantation. 2013 May 27;95(10):1284-91. doi: 10.1097/TP.0b013e318288ca4d.

PMID:
23507699
5.

Analysis of incidence, risk factors and clinical outcome of thromboembolic and bleeding events in 431 allogeneic hematopoietic stem cell transplantation recipients.

Labrador J, Lopez-Anglada L, Perez-Lopez E, Lozano FS, Lopez-Corral L, Sanchez-Guijo FM, Vazquez L, Perez Rivera JA, Martin-Herrero F, Sanchez-Barba M, Guerrero C, del Cañizo MC, Caballero MD, San Miguel JF, Alberca I, Gonzalez-Porras JR.

Haematologica. 2013 Mar;98(3):437-43. doi: 10.3324/haematol.2012.069559. Epub 2012 Aug 16.

6.

Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects.

Garcia-Gomez A, Ocio EM, Crusoe E, Santamaria C, Hernández-Campo P, Blanco JF, Sanchez-Guijo FM, Hernández-Iglesias T, Briñón JG, Fisac-Herrero RM, Lee FY, Pandiella A, San Miguel JF, Garayoa M.

PLoS One. 2012;7(4):e34914. doi: 10.1371/journal.pone.0034914. Epub 2012 Apr 23.

7.

Bone marrow transplantation extends its scope.

Sánchez-Guijo FM, Orfao A, Del Cañizo MC.

Adv Exp Med Biol. 2012;741:121-34. doi: 10.1007/978-1-4614-2098-9_9.

PMID:
22457107
8.

Impaired expression of DICER, DROSHA, SBDS and some microRNAs in mesenchymal stromal cells from myelodysplastic syndrome patients.

Santamaría C, Muntión S, Rosón B, Blanco B, López-Villar O, Carrancio S, Sánchez-Guijo FM, Díez-Campelo M, Alvarez-Fernández S, Sarasquete ME, de las Rivas J, González M, San Miguel JF, Del Cañizo MC.

Haematologica. 2012 Aug;97(8):1218-24. doi: 10.3324/haematol.2011.054437. Epub 2012 Feb 27.

9.

Optimisation of mesenchymal stromal cells karyotyping analysis: implications for clinical use.

Muntión S, Sánchez-Guijo FM, Carrancio S, Villarón E, López O, Diez-Campelo M, San Miguel JF, del Cañizo MC.

Transfus Med. 2012 Apr;22(2):122-7. doi: 10.1111/j.1365-3148.2012.01134.x. Epub 2012 Feb 1.

PMID:
22296109
10.

Bone marrow mesenchymal stem cells for improving hematopoietic function: an in vitro and in vivo model. Part 2: Effect on bone marrow microenvironment.

Carrancio S, Blanco B, Romo C, Muntion S, Lopez-Holgado N, Blanco JF, Briñon JG, San Miguel JF, Sanchez-Guijo FM, del Cañizo MC.

PLoS One. 2011;6(10):e26241. doi: 10.1371/journal.pone.0026241. Epub 2011 Oct 20.

11.

Allogeneic mesenchymal stem cell therapy for refractory cytopenias after hematopoietic stem cell transplantation.

Sánchez-Guijo FM, López-Villar O, López-Anglada L, Villarón EM, Muntión S, Díez-Campelo M, Perez-Simón JA, San Miguel JF, Caballero D, del Cañizo MC.

Transfusion. 2012 May;52(5):1086-91. doi: 10.1111/j.1537-2995.2011.03400.x. Epub 2011 Oct 24.

PMID:
22023454
12.

Titanium and tantalum as mesenchymal stem cell scaffolds for spinal fusion: an in vitro comparative study.

Blanco JF, Sánchez-Guijo FM, Carrancio S, Muntion S, García-Briñon J, del Cañizo MC.

Eur Spine J. 2011 Aug;20 Suppl 3:353-60. doi: 10.1007/s00586-011-1901-8. Epub 2011 Jul 16.

13.

Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial.

Pérez-Simon JA, López-Villar O, Andreu EJ, Rifón J, Muntion S, Diez Campelo M, Sánchez-Guijo FM, Martinez C, Valcarcel D, Cañizo CD.

Haematologica. 2011 Jul;96(7):1072-6. doi: 10.3324/haematol.2010.038356. Epub 2011 Mar 10.

14.

[Cell-Production Units for stem cell clinical research: basic aspects for their development and optimization].

López-Holgado N, López-Villar O, Sánchez-Guijo FM, del Cañizo MC.

Med Clin (Barc). 2012 Jan 21;138(1):31-6. doi: 10.1016/j.medcli.2010.10.014. Epub 2011 Mar 3. Review. Spanish. No abstract available.

PMID:
21376351
15.

Evaluation of tolerability and efficacy of imatinib mesylate in elderly patients with chronic phase CML: ELDERGLI study.

Sánchez-Guijo FM, Durán S, Galende J, Boqué C, Nieto JB, Balanzat J, Gracia A, García I, Avellaneda-Molina C, Moreno MV, Luño-Fernandez E, Hermosilla M, Sanchez-Varela JM, Dios A, López-Garrido P, Giraldo P, Bargay J, Domingo JM, Soler A, Salinas R, del Cañizo MC.

Leuk Res. 2011 Sep;35(9):1184-7. doi: 10.1016/j.leukres.2011.01.017. Epub 2011 Feb 12.

PMID:
21316760
16.

Effect of vitamin D treatment in chronic GVHD.

Silva F, Pérez-Simón JA, Caballero-Velazquez T, Sánchez-Guijo FM, Villanueva-Gomez F, Vazquez L, del Cañizo C, Caballero D, San Miguel J.

Bone Marrow Transplant. 2011 Oct;46(10):1395-7. doi: 10.1038/bmt.2010.317. Epub 2011 Jan 17. No abstract available.

17.

Ischemic stroke associated with the infusion of DMSO-cryopreserved auto-PBSCs.

González-López TJ, Sánchez-Guijo FM, Ortín A, Crusoe E, Cordoba I, Corral M, Vazquez L, Caballero MD.

Bone Marrow Transplant. 2011 Jul;46(7):1035-6. doi: 10.1038/bmt.2010.242. Epub 2010 Oct 18. No abstract available.

PMID:
20956954
18.

Isolation and characterization of mesenchymal stromal cells from human degenerated nucleus pulposus: comparison with bone marrow mesenchymal stromal cells from the same subjects.

Blanco JF, Graciani IF, Sanchez-Guijo FM, Muntión S, Hernandez-Campo P, Santamaria C, Carrancio S, Barbado MV, Cruz G, Gutierrez-Cosío S, Herrero C, San Miguel JF, Briñon JG, del Cañizo MC.

Spine (Phila Pa 1976). 2010 Dec 15;35(26):2259-65. doi: 10.1097/BRS.0b013e3181cb8828.

PMID:
20622750
19.

Liver function tests and absolute lymphocyte count at day +100 are predictive factors for extensive and severe chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplant.

Silva F, Pérez-Simón JA, Caballero Velazquez T, Encinas C, Sánchez-Guijo FM, Díez-Campelo M, Colado E, Martín J, Villanueva-Gomez F, Vazquez L, Del Cañizo C, Caballero D, San Miguel J.

Am J Hematol. 2010 Apr;85(4):290-3. doi: 10.1002/ajh.21613. No abstract available.

20.

Prospective comparative analysis of the angiogenic capacity of monocytes and CD133+ cells in a murine model of hind limb ischemia.

López-Holgado N, Alberca M, Sánchez-Guijo FM, Villarón EM, Rivas JV, López-Novoa JM, Briñón JG, Arévalo MA, Oterino E, Santamaría C, San Miguel JF, del Cañizo MC.

Cytotherapy. 2009;11(8):1041-51. doi: 10.3109/14653240903191719.

PMID:
19929468
21.

Both CD133(+) cells and monocytes provide significant improvement for hindlimb ischemia, although they do not transdifferentiate into endothelial cells.

Sanchez-Guijo FM, Oterino E, Barbado MV, Carrancio S, Lopez-Holgado N, Muntion S, Hernandez-Campo P, Sanchez-Abarca LI, Perez-Simon JA, San Miguel JF, Briñon JG, del Cañizo MC.

Cell Transplant. 2010;19(1):103-12. doi: 10.3727/096368909X476869. Epub 2009 Oct 9.

PMID:
19818207
22.

Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population.

Blanco B, Pérez-Simón JA, Sánchez-Abarca LI, Caballero-Velazquez T, Gutierrez-Cossío S, Hernández-Campo P, Díez-Campelo M, Herrero-Sanchez C, Rodriguez-Serrano C, Santamaría C, Sánchez-Guijo FM, Del Cañizo C, San Miguel JF.

Haematologica. 2009 Jul;94(7):975-83. doi: 10.3324/haematol.2008.005017. Epub 2009 Jun 8.

23.

Multiparametric comparison of mesenchymal stromal cells obtained from trabecular bone by using a novel isolation method with those obtained by iliac crest aspiration from the same subjects.

Sanchez-Guijo FM, Blanco JF, Cruz G, Muntion S, Gomez M, Carrancio S, Lopez-Villar O, Barbado MV, Sanchez-Abarca LI, Blanco B, Briñon JG, del Cañizo MC.

Cell Tissue Res. 2009 Jun;336(3):501-7. doi: 10.1007/s00441-009-0778-x. Epub 2009 Apr 9.

PMID:
19357871
24.

Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors.

Garayoa M, Garcia JL, Santamaria C, Garcia-Gomez A, Blanco JF, Pandiella A, Hernández JM, Sanchez-Guijo FM, del Cañizo MC, Gutiérrez NC, San Miguel JF.

Leukemia. 2009 Aug;23(8):1515-27. doi: 10.1038/leu.2009.65. Epub 2009 Apr 9.

PMID:
19357701
25.

Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q- syndrome.

Lopez-Villar O, Garcia JL, Sanchez-Guijo FM, Robledo C, Villaron EM, Hernández-Campo P, Lopez-Holgado N, Diez-Campelo M, Barbado MV, Perez-Simon JA, Hernández-Rivas JM, San-Miguel JF, del Cañizo MC.

Leukemia. 2009 Apr;23(4):664-72. doi: 10.1038/leu.2008.361. Epub 2009 Jan 8.

PMID:
19151777
26.

Multitargeted sequential therapy with MK-0457 and dasatinib followed by stem cell transplantation for T315I mutated chronic myeloid leukemia.

Sanchez-Guijo FM, Lopez-Jimenez J, Gonzalez T, Santamaría C, González M, Del Cañizo MC.

Leuk Res. 2009 Jun;33(6):e20-2. doi: 10.1016/j.leukres.2008.10.020. Epub 2008 Nov 26. No abstract available.

PMID:
19038446
27.

Prognostic factors of chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation: the national institutes health scale plus the type of onset can predict survival rates and the duration of immunosuppressive therapy.

Pérez-Simón JA, Encinas C, Silva F, Arcos MJ, Díez-Campelo M, Sánchez-Guijo FM, Colado E, Martín J, Vazquez L, Del Cañizo C, Caballero D, San Miguel J.

Biol Blood Marrow Transplant. 2008 Oct;14(10):1163-1171. doi: 10.1016/j.bbmt.2008.07.015.

28.

Effects of imatinib mesylate on normal bone marrow cells from chronic myeloid leukemia patients in complete cytogenetic response.

Sanchez-Guijo FM, Hernandez JM, Lumbreras E, Morais P, Santamaría C, Garcia JL, Gutierrez NC, Miguel JF, Del Cañizo MC.

Leuk Res. 2009 Jan;33(1):170-3. doi: 10.1016/j.leukres.2008.07.014. Epub 2008 Aug 21.

PMID:
18722011
29.

Beclometasone dipropionate: a topically active corticosteroid for the treatment of gastrointestinal graft-versus-host disease.

Díez-Campelo M, Sánchez-Guijo FM, Pérez-Simón JA.

Expert Opin Investig Drugs. 2008 Sep;17(9):1389-401. doi: 10.1517/13543784.17.9.1389 . Erratum in: Expert Opin Investig Drugs. 2008 Oct;17(10):1617. Simón, José A Pérez [corrected to Pérez-Simón, José A].

PMID:
18694371
30.

The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes.

Tabera S, Pérez-Simón JA, Díez-Campelo M, Sánchez-Abarca LI, Blanco B, López A, Benito A, Ocio E, Sánchez-Guijo FM, Cañizo C, San Miguel JF.

Haematologica. 2008 Sep;93(9):1301-9. doi: 10.3324/haematol.12857. Epub 2008 Jul 18.

31.

Optimization of mesenchymal stem cell expansion procedures by cell separation and culture conditions modification.

Carrancio S, López-Holgado N, Sánchez-Guijo FM, Villarón E, Barbado V, Tabera S, Díez-Campelo M, Blanco J, San Miguel JF, Del Cañizo MC.

Exp Hematol. 2008 Aug;36(8):1014-21. doi: 10.1016/j.exphem.2008.03.012. Epub 2008 May 12.

PMID:
18468767
32.

Emergency surgery of the abdominal aorta in a porcine model: two sequential experiments.

Lozano FS, Rodríguez JM, García-Criado FJ, Gonzalez-Porras JR, Sanchez-Guijo FM, Sanchez-Conde P, García-Sanchez JE.

World J Surg. 2008 Apr;32(4):642-7. doi: 10.1007/s00268-007-9346-2.

PMID:
18204801
33.

In leukapheresis products from non-Hodgkin's lymphoma patients, the immature hematopoietic progenitors show higher CD90 and CD34 antigenic expression.

Villaron EM, Almeida J, Lopez-Holgado N, Sanchez-Guijo FM, Alberca M, Blanco B, Sanchez-Abarca LI, Lopez O, Perez-Simon JA, San Miguel JF, del Cañizo MC.

Transfus Apher Sci. 2007 Oct;37(2):145-56. Epub 2007 Nov 5.

PMID:
17983836
34.

Alteration of marrow cell gene expression, protein production, and engraftment into lung by lung-derived microvesicles: a novel mechanism for phenotype modulation.

Aliotta JM, Sanchez-Guijo FM, Dooner GJ, Johnson KW, Dooner MS, Greer KA, Greer D, Pimentel J, Kolankiewicz LM, Puente N, Faradyan S, Ferland P, Bearer EL, Passero MA, Adedi M, Colvin GA, Quesenberry PJ.

Stem Cells. 2007 Sep;25(9):2245-56. Epub 2007 Jun 7.

35.

Peripheral endothelial progenitor cells (CD133 +) for therapeutic vasculogenesis in a patient with critical limb ischemia. One year follow-up.

Cañizo MC, Lozano F, González-Porras JR, Barros M, López-Holgado N, Briz E, Sánchez-Guijo FM.

Cytotherapy. 2007;9(1):99-102.

PMID:
17354105
36.

Launching a clinical program of stem cell therapy for cardiovascular repair.

Sánchez PL, Sánchez-Guijo FM, Villa A, del Cañizo C, Arnold R, San Román JA, Fernández-Avilés F.

Nat Clin Pract Cardiovasc Med. 2007 Feb;4 Suppl 1:S123-9. Review.

PMID:
17230210
37.

Stem cell continuum: directed differentiation hotspots.

Colvin GA, Dooner MS, Dooner GJ, Sanchez-Guijo FM, Demers DA, Abedi M, Ramanathan M, Chung S, Pascual S, Quesenberry PJ.

Exp Hematol. 2007 Jan;35(1):96-107.

PMID:
17198878
38.

Complete remission of subcutaneous panniculitic T-cell lymphoma after allogeneic transplantation.

Pérez-Persona E, Mateos-Mazón JJ, López-Villar O, Arcos MJ, Encinas C, Graciani IF, Ocio EM, Sánchez-Guijo FM, Caballero MD.

Bone Marrow Transplant. 2006 Dec;38(12):821-2. Epub 2006 Oct 23. No abstract available.

PMID:
17057727
39.

Oral beclomethasone dipropionate for the treatment of gastrointestinal acute graft-versus-host disease (GVHD).

Castilla C, Pérez-Simón JA, Sanchez-Guijo FM, Díez-Campelo M, Ocio E, Pérez-Persona E, López-Villar O, Vazquez L, Caballero D, San Miguel JF.

Biol Blood Marrow Transplant. 2006 Sep;12(9):936-41.

40.

The marrow cell continuum: stochastic determinism.

Quesenberry P, Abedi M, Dooner M, Colvin G, Sanchez-Guijo FM, Aliotta J, Pimentel J, Dooner G, Greer D, Demers D, Keaney P, Peterson A, Luo L, Foster B.

Folia Histochem Cytobiol. 2005;43(4):187-90. Review.

41.

Posttransplant hematopoiesis in patients undergoing sibling allogeneic stem cell transplantation reflects that of their respective donors although with a lower functional capability.

Sanchez-Guijo FM, Sanchez-Abarca LI, Villaron E, Lopez-Holgado N, Alberca M, Vazquez L, Perez-Simon JA, Lopez-Fidalgo J, Orfao A, Caballero MD, Del Cañizo MC, San Miguel JF.

Exp Hematol. 2005 Aug;33(8):935-43.

PMID:
16038787
42.

Long-term immune recovery of patients undergoing allogeneic stem cell transplantation: a comparison with their respective sibling donors.

Sanchez-Guijo FM, Sanchez-Abarca LI, Bueno C, Villaron E, Lopez-Holgado N, Vazquez L, Lopez-Fidalgo J, Perez-Simon JA, Caballero MD, del Cañizo MC, Orfao A, San Miguel JF.

Biol Blood Marrow Transplant. 2005 May;11(5):354-61.

43.

Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena.

Ocio EM, Sanchez-Guijo FM, Diez-Campelo M, Castilla C, Blanco OJ, Caballero D, San Miguel JF.

Am J Hematol. 2005 Apr;78(4):302-5.

44.

CD34 + cell dose and outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation.

Díez-Campelo M, Pérez-Simón JA, Ocio EM, Castilla C, González-Porras JR, Sánchez-Guijo FM, Vázquez L, Caballero MD, Cañizo MC, San Miguel JF.

Leuk Lymphoma. 2005 Feb;46(2):177-83. Review.

PMID:
15621799
45.

Mesenchymal stem cells are present in peripheral blood and can engraft after allogeneic hematopoietic stem cell transplantation.

Villaron EM, Almeida J, López-Holgado N, Alcoceba M, Sánchez-Abarca LI, Sanchez-Guijo FM, Alberca M, Pérez-Simon JA, San Miguel JF, Del Cañizo MC.

Haematologica. 2004 Dec;89(12):1421-7.

Supplemental Content

Loading ...
Support Center